Zhengzhou, China

Dapeng Zou

This inventor holds 1 USPTO granted patent. Top assignee: Tetranov International Inc.. Active years: 2014.


Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2014

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Dapeng Zou: Innovator in Tyrosine Kinase Inhibition

Introduction

Dapeng Zou is a prominent inventor based in Zhengzhou, China. He has made significant contributions to the field of medicinal chemistry, particularly in the development of novel compounds for therapeutic applications.

Latest Patents

Dapeng Zou holds a patent for "Bis-quinazoline derivatives as inhibitors for epidermal growth factor receptor (EGFR) tyrosine kinase." This invention discloses novel bis-quinazoline derivatives that serve as tyrosine kinase inhibitors. The patent details the synthesis of these compounds and outlines innovative methods for treating diseases or disorders mediated by tyrosine kinase. Specifically, the invention provides tethered quinazoline derivative dimers as inhibitors to the EGFR tyrosine kinase. It also includes pharmaceutical compositions and their therapeutic uses for treating EGFR kinase-mediated diseases, such as various cancers.

Career Highlights

Dapeng Zou is associated with Tetranov International Inc., where he continues to advance his research and development efforts. His work focuses on creating effective treatments for serious health conditions through innovative chemical compounds.

Collaborations

Dapeng Zou collaborates with notable colleagues, including Chengshan Niu and Ruiyun Guo, to further enhance the impact of his research in the field.

Conclusion

Dapeng Zou's contributions to the development of bis-quinazoline derivatives highlight his commitment to advancing medical science. His innovative work in tyrosine kinase inhibition has the potential to lead to significant advancements in cancer treatment.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…